• Bloomberg

  • SHARE

Pfizer Inc. and partner BioNTech SE have said their COVID-19 vaccine was safe and produced strong antibody responses in children age 5 to 11 in a large-scale trial, findings that could pave the way for the start of vaccinations for grade-school kids within months.

The long-awaited results offer one of the first looks at how well a COVID-19 vaccine could work for younger children. Pressure to immunize kids has been on the climb in the U.S., where a new school year has started just as the delta variant is fueling a surge in cases.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)